A Phase I/II, Open-Label Dose Escalation Trial to Evaluate the Safety and Efficacy of Two Dose Levels of PNEUMOSTEM in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD)

Trial Profile

A Phase I/II, Open-Label Dose Escalation Trial to Evaluate the Safety and Efficacy of Two Dose Levels of PNEUMOSTEM in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Bronchopulmonary dysplasia
  • Focus Adverse reactions
  • Sponsors Medipost
  • Most Recent Events

    • 18 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 May 2016 According to Medipost media relese, 90% of the study is complete.
    • 22 Mar 2016 Planned End Date changed from 1 Feb 2018 to 1 May 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top